CN Stock MarketDetailed Quotes
300878 Zhejiang Wecome Pharmaceutical
- 20.57
- +1.25+6.47%
Market Closed Dec 12 15:00 CST
2.98BMarket Cap-89.43P/E (TTM)
20.99High19.27Low81.39KlotVolume19.44Open19.32Pre Close164.47MTurnover5.65%Turnover RatioLossP/E (Static)144.79MShares26.1352wk High2.21P/B2.96BFloat Cap13.3152wk Low23.18Limit Up144.12MShs Float59.90Historical High15.46Limit Down8.90%Amplitude13.31Historical Low0.25Dividend TTM20.21Avg Price35.94KlotAsk1.22%Div YieldTTM100Lot Size42.01KlotBid
Zhejiang Wecome Pharmaceutical Key Stats
All
YOY
| (Q9)Sep 30, 2024 | (Q6)Jun 30, 2024 | (Q3)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q9)Sep 30, 2023 | (Q6)Jun 30, 2023 | (Q3)Mar 31, 2023 | (FY)Dec 31, 2022 | (Q9)Sep 30, 2022 | (Q6)Jun 30, 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total operating revenue | -14.16%370.85M | -6.15%296.99M | 2.15%199.95M | -2.41%519.62M | -8.93%432M | 7.04%316.44M | 6.50%195.74M | -15.88%532.44M | -5.40%474.35M | -10.91%295.62M |
| Operating revenue | -14.16%370.85M | -6.15%296.99M | 2.15%199.95M | -2.41%519.62M | -8.93%432M | 7.04%316.44M | 6.50%195.74M | -15.88%532.44M | -5.40%474.35M | -10.91%295.62M |
| Other operating revenue | ---- | 9.42%2.46M | ---- | --5.07M | ---- | 12.56%2.25M | ---- | ---- | ---- | 412.42%2M |
| Total operating cost | 15.38%414.72M | 8.07%285.14M | 5.33%173.89M | 13.37%560.07M | -5.05%359.42M | 7.03%263.85M | 1.34%165.1M | -8.16%494.02M | -3.94%378.54M | -5.44%246.51M |
| Operating cost | 7.90%195.11M | 2.29%143.89M | -3.83%102.13M | 17.66%257.76M | 4.36%180.82M | 21.95%140.67M | 20.12%106.2M | 7.19%219.08M | 29.03%173.26M | 21.38%115.35M |
| Operating tax surcharges | 599.98%9.05M | 719.62%5.58M | 2,717.77%4.72M | 47.68%2.81M | 22.67%1.29M | -30.08%680.79K | -79.22%167.57K | -60.27%1.91M | -67.27%1.05M | -51.49%973.65K |
| Operating expense | 32.10%163.24M | 26.26%105.65M | 30.78%52.34M | 7.85%208.19M | -13.44%123.57M | -10.95%83.68M | -29.87%40.02M | -28.50%193.03M | -37.08%142.75M | -35.33%93.97M |
| Administration expense | 15.76%33.17M | 16.08%21.78M | 25.20%10.77M | 9.60%40.94M | 3.38%28.65M | 6.10%18.77M | -1.88%8.61M | 50.93%37.36M | 55.69%27.72M | 51.42%17.69M |
| Financial expense | -62.31%1.97M | -53.62%1.65M | -24.60%956.97K | 127.40%7.56M | -8.11%5.22M | 423.19%3.57M | 2,018.35%1.27M | 209.69%3.33M | 253.39%5.69M | 126.32%682.06K |
| -Interest expense (Financial expense) | -31.32%4.2M | -21.14%3.18M | -6.59%1.24M | 74.69%9.45M | -14.31%6.12M | 293.39%4.04M | 199.35%1.33M | 150.52%5.41M | 9,754.63%7.14M | 1,316.61%1.03M |
| -Interest Income (Financial expense) | -65.34%-2.31M | -65.70%-1.58M | -43.98%-616.54K | 11.97%-1.98M | 11.73%-1.4M | 19.68%-951.67K | 19.84%-428.22K | 57.46%-2.25M | 62.71%-1.59M | 59.30%-1.18M |
| Research and development | -38.69%12.18M | -60.08%6.58M | -66.40%2.97M | 8.84%42.8M | -29.22%19.87M | -7.66%16.48M | 13.23%8.84M | 6.23%39.32M | 80.05%28.07M | 92.54%17.85M |
| Credit Impairment Loss | -171.10%-6.59M | -135.40%-3.95M | -4.68%-4.98M | 256.85%11.46M | 1,308.75%9.27M | 605.90%11.14M | -298.51%-4.76M | 13.10%-7.31M | 107.75%657.82K | 118.47%1.58M |
| Asset Impairment Loss | 1.70%-123.73K | -33.17%-92.19K | 0.00%-34.61K | -232.80%-736.97K | 33.45%-125.87K | 45.10%-69.22K | 45.10%-34.61K | -152.29%-221.44K | ---189.13K | ---126.09K |
| Other net revenue | 325.25%91.93M | -91.93%1.72M | -76.25%569.47K | 49.19%39.43M | 26.54%21.62M | 25.79%21.3M | -55.11%2.4M | 547.51%26.43M | 493.91%17.08M | 540.19%16.93M |
| Fair value change income | ---- | ---- | --2.19M | --4.56M | ---- | ---- | ---- | ---- | ---- | ---- |
| Invest income | 1,178.66%92.11M | -70.23%2.14M | -79.11%1.25M | -6.22%13.87M | 245.71%7.2M | 245.71%7.2M | 186.02%5.96M | 5,494.56%14.79M | --2.08M | --2.08M |
| -Including: Investment income associates | ---- | ---- | ---- | ---217.58K | ---- | ---- | ---- | ---- | ---- | ---- |
| Asset deal income | -2,120.19%-251.11K | -2,282.77%-271.32K | ---30.53K | 99.08%-5.82K | 122.88%12.43K | 120.83%12.43K | ---- | -1,038.94%-634.52K | -180.86%-54.33K | -3,067.29%-59.66K |
| Other revenue | 28.96%6.78M | 28.90%3.88M | 77.11%2.17M | -48.10%10.28M | -63.93%5.26M | -77.62%3.01M | 32.60%1.23M | 61.72%19.81M | 29.17%14.59M | 20.22%13.46M |
| Operating profit | -48.98%48.06M | -81.64%13.57M | -19.39%26.63M | -101.56%-1.01M | -16.56%94.2M | 11.87%73.89M | 26.06%33.04M | -34.59%64.85M | 2.41%112.89M | -10.47%66.05M |
| Add:Non operating Income | 5,654.69%3.08M | 5,502.90%2.8M | -68.17%35.8K | 25.83%518.79K | -88.17%53.56K | -85.40%49.96K | -59.10%112.46K | -59.96%412.29K | -53.84%452.6K | -32.38%342.33K |
| Less:Non operating expense | 41.73%7.32M | -53.48%269.46K | -38.69%318.76K | 150.33%5.29M | 1,022.19%5.16M | 95.41%579.28K | 184.92%519.93K | 1,371.00%2.11M | 580.66%459.96K | 916.37%296.44K |
| Total profit | -50.80%43.83M | -78.06%16.1M | -19.25%26.35M | -109.16%-5.79M | -21.08%89.09M | 11.00%73.36M | 24.07%32.63M | -36.87%63.15M | 1.56%112.89M | -10.99%66.1M |
| Less:Income tax cost | -113.05%-2.38M | -98.50%117.51K | -57.48%1.96M | -97.08%398.59K | -0.15%18.22M | -8.59%7.84M | 45.41%4.61M | 292.64%13.67M | -0.78%18.24M | -19.87%8.57M |
| Net profit | -34.81%46.21M | -75.61%15.98M | -12.95%24.39M | -112.50%-6.18M | -25.12%70.87M | 13.92%65.53M | 21.14%28.02M | -48.75%49.48M | 2.02%94.64M | -9.49%57.52M |
| Net profit from continuing operation | -34.81%46.21M | -75.61%15.98M | -12.95%24.39M | -112.50%-6.18M | -25.12%70.87M | 13.92%65.53M | 21.14%28.02M | -48.75%49.48M | 2.02%94.64M | -9.49%57.52M |
| Less:Minority Profit | 38.41%2.11M | 97.62%1.79M | -88.95%54.35K | 175.94%1.85M | 113.73%1.52M | 68.98%904.87K | 135.91%491.76K | 1,197.89%671.9K | 1,387.39%712.44K | 344.89%535.5K |
| Net profit of parent company owners | -36.41%44.1M | -78.04%14.19M | -11.59%24.33M | -116.47%-8.04M | -26.17%69.35M | 13.40%64.62M | 20.10%27.53M | -49.42%48.81M | 1.31%93.93M | -10.64%56.99M |
| Earning per share | ||||||||||
| Basic earning per share | -35.42%0.31 | -77.78%0.1 | -10.53%0.17 | -117.65%-0.06 | -26.01%0.48 | 14.33%0.45 | -33.31%0.19 | -49.25%0.34 | -43.72%0.6487 | -50.37%0.3936 |
| Diluted earning per share | -35.42%0.31 | -77.78%0.1 | -10.53%0.17 | -117.65%-0.06 | -26.01%0.48 | 14.33%0.45 | -33.31%0.19 | -49.25%0.34 | -43.72%0.6487 | -50.37%0.3936 |
| Other composite income | ||||||||||
| Total composite income | -34.81%46.21M | -75.61%15.98M | -12.95%24.39M | -112.50%-6.18M | -25.12%70.87M | 13.92%65.53M | 21.14%28.02M | -48.75%49.48M | 2.02%94.64M | -9.49%57.52M |
| Total composite income of parent company owners | -36.41%44.1M | -78.04%14.19M | -11.59%24.33M | -116.47%-8.04M | -26.17%69.35M | 13.40%64.62M | 20.10%27.53M | -49.42%48.81M | 1.31%93.93M | -10.64%56.99M |
| Total composite income of minority owners | 38.41%2.11M | 97.62%1.79M | -88.95%54.35K | 175.94%1.85M | 113.73%1.52M | 68.98%904.87K | 135.91%491.76K | 1,197.89%671.9K | 1,387.39%712.44K | 344.89%535.5K |
| Currency Unit | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY |
| Accounting Standards | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) |
| Audit Opinions | -- | -- | -- | Reservations with explanatory notes | -- | -- | -- | Unqualified opinion | -- | -- |
| Auditor | -- | -- | -- | Tianjian Certified Public Accountants (Special General Partnership) | -- | -- | -- | Tianjian Certified Public Accountants (Special General Partnership) | -- | -- |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.
Heat List
CN
Overall
Symbol
Price
% Chg
No Data
